Despite what its CEO called a "challenging" 2012 rife with "growing pains," Cepheid last week reported a 15 percent increase in fourth-quarter year-over-year revenues and a 19 percent increase in full-year revenues.

Cepheid also provided an update on its recent manufacturing woes and its high-burden developing country program, noting that variables associated with these items affected the company's ability to make good on its 2012 guidance, and have been factored into Cepheid's guidance for the coming year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.